CNMD
CONMED Corporation NYSE$35.88
Mkt Cap $1.1B
52w Low $33.21
9.6% of range
52w High $61.08
50d MA $38.66
200d MA $44.15
P/E (TTM)
24.2x
EV/EBITDA
11.6x
P/B
1.1x
Debt/Equity
0.8x
ROE
4.5%
P/FCF
8.4x
RSI (14)
—
ATR (14)
—
Beta
0.99
50d MA
$38.66
200d MA
$44.15
Avg Volume
449.9K
About
CONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for surgical procedures worldwide. It offers orthopedic surgery products, including TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and PopLok Knotless Suture Anchors, which provide unique clinical solutions to orthopedic surgeons for the…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 29, 2026 | AMC | 0.82 | 0.89 | +8.5% | 35.96 | +3.0% | +1.9% | +2.3% | -0.2% | — | — | — |
| Jan 28, 2026 | AMC | 1.32 | 1.43 | +8.3% | 38.69 | +0.2% | -3.6% | -0.8% | +1.3% | +0.3% | +3.2% | — |
| Nov 5, 2025 | AMC | 1.05 | 1.08 | +2.9% | 44.44 | -3.2% | -0.5% | -1.1% | -1.1% | +0.6% | -2.0% | — |
| Jul 30, 2025 | AMC | 1.13 | 1.15 | +1.8% | 50.14 | +4.1% | +2.0% | +4.3% | +6.7% | +6.7% | +1.8% | — |
| Apr 30, 2025 | AMC | 0.81 | 0.95 | +17.3% | 49.11 | +12.0% | +16.5% | +17.5% | +16.0% | +13.8% | +14.1% | — |
| Feb 5, 2025 | AMC | 1.20 | 1.34 | +11.7% | 74.00 | -5.3% | -9.0% | -10.2% | -9.0% | -12.1% | -15.5% | — |
| Oct 30, 2024 | AMC | 0.99 | 1.05 | +6.1% | 65.26 | +0.0% | +4.6% | +7.9% | +8.0% | +13.4% | +15.9% | — |
| Jul 31, 2024 | AMC | 0.91 | 0.98 | +7.7% | 69.04 | -8.2% | -5.4% | -0.5% | -4.9% | -5.2% | -3.8% | — |
| Apr 24, 2024 | AMC | 0.74 | 0.79 | +6.8% | 70.01 | -9.5% | -11.6% | -6.0% | -4.0% | -2.9% | -2.4% | — |
| Jan 31, 2024 | AMC | 1.11 | 1.06 | -4.5% | 95.60 | -12.4% | -12.4% | -15.4% | -13.7% | -12.8% | -12.8% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 1 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $36.66 | $36.94 | +0.8% | +0.4% | — | — | — | — |
| Apr 30 | JP Morgan | Maintains | Neutral → Neutral | — | $35.96 | $37.04 | +3.0% | +1.9% | +2.3% | — | — | — |
| Mar 17 | Piper Sandler | Downgrade | Overweight → Neutral | — | $37.41 | $37.30 | -0.3% | -0.2% | -1.9% | -1.6% | -3.9% | -2.1% |
| Jan 29 | Needham | Maintains | Hold → Hold | — | $38.69 | $38.77 | +0.2% | -3.6% | -0.8% | +1.3% | +0.3% | +3.2% |
| Jan 29 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $38.69 | $38.77 | +0.2% | -3.6% | -0.8% | +1.3% | +0.3% | +3.2% |
| Dec 8 | BofA Securities | Maintains | Neutral → Neutral | — | $40.07 | $40.07 | +0.0% | +1.2% | -2.7% | -2.6% | -0.5% | +1.9% |
| Nov 6 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $44.44 | $43.00 | -3.2% | -0.5% | -1.1% | -1.1% | +0.6% | -2.0% |
| Nov 6 | Piper Sandler | Maintains | Overweight → Overweight | — | $44.44 | $43.00 | -3.2% | -0.5% | -1.1% | -1.1% | +0.6% | -2.0% |
| Nov 6 | JP Morgan | Maintains | Neutral → Neutral | — | $44.44 | $43.00 | -3.2% | -0.5% | -1.1% | -1.1% | +0.6% | -2.0% |
| Jul 31 | Piper Sandler | Maintains | Overweight → Overweight | — | $50.14 | $52.22 | +4.1% | +2.0% | +4.3% | +6.7% | +6.7% | +1.8% |
Recent Filings
8-K
CONMED Corporation -- 8-K Filing
CONMED Corporation reported Q1 2026 sales of $317.0 million, down 1.3% year-over-year, signaling modest revenue headwinds despite operational continuity.
Apr 29
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
CONMED's leadership transition on March 13, 2026 creates uncertainty about strategic direction and execution capability, potentially impacting near-term stock performance until new management's vision becomes clear.
Mar 13
Data updated apr 25, 2026 2:14am
· Source: massive.com